

**SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER**  
**Pursuant to Rule 13a-16 or 15d-16 under**  
**the Securities Exchange Act of 1934**

For the month of: October 2018

Commission File Number: 001-35776

---

**ACASTI PHARMA INC.**  
(Name of Registrant)

---

**545 Promende du Centropolis**  
**Suite 100**  
**Laval, Québec**  
**Canada H7T 0A3**  
(Address of Principal Executive Office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

---

On October 15, 2018, Acasti Pharma Inc. (the "Corporation") received written notification from the Listing Qualifications Department of The Nasdaq Stock Market that the Corporation regained compliance with Listing Rule 5550(a)(2), which requires a minimum bid price of U.S.\$1.00 per share. The Corporation is now fully compliant with all Nasdaq rules and this matter is now closed.

---

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**ACASTI PHARMA INC.**

Date: October 15, 2018

By: /s/ Jan D'Alvise  
Name: Jan D'Alvise  
Title: Chief Executive Officer